Status:
COMPLETED
Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator
Lead Sponsor:
University of British Columbia
Conditions:
Hepatitis B
Eligibility:
All Genders
19-60 years
Phase:
PHASE1
PHASE2
Brief Summary
This study will look at what happens to the level of protection against hepatitis B (HB) disease if a 'helper' gel is applied to the skin over the injection site of a small dose of hepatitis B vaccine...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Previously vaccinated with conventional hepatitis B vaccine series 10 or more years ago
- Generally healthy
- Is and has been free of HB disease and/or is negative to core antibody
- Known to have sero-converted to positive after vaccine series (without extra doses)
- Speaks and understands English adequately
- Available for all 4 visits within the designated timelines (30 days)
- No allergies to HB vaccine or components
- No blood or blood components within previous 6 months
- Not pregnant or breastfeeding
Exclusion
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00175435
Start Date
August 1 2005
End Date
April 1 2007
Last Update
November 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver General Hospital Vaccine Education Centre
Vancouver, British Columbia, Canada